Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...

The ADCs mAb attaches to specific antigens on the surface of tumor cells, and ADCs are internalized into tumor cells during ... at the forefront of advancing ADC therapy for treating solid tumors ...

They help the immune system recognize cancer cells that impersonate healthy cells. However, the effectiveness of these ...

iADCs target and destroy cancer ... ADC development. ADCs could hold the key to the targeted delivery of strong cytotoxic drugs to tumor cells. The idea is to link the cytotoxic drug to a tumor ...

The phase 1b trial represented an early test of whether those claimed advantages will translate into a compelling drug candidate. ADC provided ... pancreatic cancer and non-small cell lung cancer.

ZL-1310 is a novel ADC in Zai Lab’s growing, global oncology pipeline that targets Delta-like ligand 3 (DLL3), an antigen that is overexpressed in many neuroendocrine tumors, is typically ...

The ADC platform is agnostic to ... Inc. “Our platform not only functionally enhances tumor antigen density but also enables multiple mechanisms for tumor cell destruction.

for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) for adult ...

The efficacy of tumor targeting ADC is limited by its exposure-related toxicity. Cancer associated fibroblasts (CAFs) surrounding tumor cells serve as a barrier for ... with select tumor types to ...